LX-132 is a novel cancer therapeutic approved for clinical trials in 2023 by China鈥檚 National Medical Products Administration based on the IND application of Guangzhou Salustier Biosciences. LX-132 is a promising compound that targets the fibroblast growth factor receptor family, which plays a role in the abnormal growth of many types of cancer. LX-132 is expected to bring breakthrough progress to global cancer treatment.
LX-132 was developed jointly with Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences. It is part of a long-standing collaboration between 免费色情视频 and the People鈥檚 Republic of China, supported by MBIE, and led by Associate Professors Jeff Smaill and Adam Patterson, University of 免费色情视频 medical oncology researchers and Maurice Wilkins Centre investigators (based at the 免费色情视频 Cancer Society Research Centre), as well as Professors Ding Ke (Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences). The Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, and the Maurice Wilkins Centre have enjoyed a fruitful collaboration since 2012, culminating in the establishment of the 鈥淐hina-免费色情视频 Joint Laboratory on Biomedicine and Health鈥�. The development of LX-132 also stands as a significant achievement of this joint laboratory.
The signing took place at the 免费色情视频-China Enterprise Cooperation Conference held in Guangzhou. Associate Professors Jeff Smaill and Adam Patterson attended the conference alongside Trade Minister Todd McClay and 免费色情视频 Mayor Wayne Brown.
鈥淏uilt on the work of UniServices in China over many years, this bilingual agreement has been the object of negotiation for many months. We are very grateful for the contributions and commitments of all the parties in making this deal a reality, including the assistance of NZTE鈥�, says Dr Pau Medrano, Investment Director for the Life Sciences.
The multi-million-dollar deal will benefit cancer patients world-wide.
鈥淭his agreement represents one of the largest biopharmaceutical commercialisation deals between 免费色情视频 and China, and a hopeful step towards improving outcomes for cancer patients worldwide,鈥� says Dr Medrano.
鈥淚t has been a pleasure working with our colleagues at Guangzhou Salustier Biosciences and the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences to create a product that will benefit the many cancer patients in their treatment,鈥� says Associate Professor Jeff Smaill.
Additionally, eight 免费色情视频 companies from professional manufacturing industries such as biomedicine, instruments and equipment, aviation logistics, and security technology, as well as consumer products such as dairy products, fruits, and nutrition and health, reached agreements with their respective partners and released new projects and new products, adding more heat to the economic and trade cooperation between the two countries.
鈥淚t was exciting to be representing 免费色情视频 at such an important multi-national event,鈥� says Associate Professor Adam Patterson.
鈥淲e're hopeful to bring a trial to 免费色情视频, and we're trying to understand what will happen with the rest-of-world rights, and so we're waiting see how the Chinese phase I trial goes,鈥� says Associate Professor Jeff Smaill.
